phgenomicsФармакогенетика и фармакогеномикаPharmacogenetics and Pharmacogenomics2588-05272686-8849LLC "Izdatelstvo OKI"10.24411/2588-0527-2018-10001phgenomics-40Research ArticleАКТУАЛЬНЫЕ ОБЗОРЫCURRENT REVIEWНовые данные по фармакогенетике в развитии артериальной гипертонии и влиянию на эффективность амлодипинаNew data on pharmacogenetics in development of arterial hypertension and effectiveness of amlodipineЛеоноваМарина ВасильевнаLeonovaM. V.anti23@mail.ruМОО «Ассоциация клинических фармакологов»РоссияAssociation of clinical pharmacologistsRussian Federation2018120320180148Copyright © Леонова М.В., 20182018Леонова М.В.Leonova M.V.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.pharmacogenetics-pharmacogenomics.ru/jour/article/view/40

Представлен научный обзор о роли фармакогенетических маркёров CYP3A5 и Р-гликопротеина в повышении артериального давления (АД) и развитии гипертонии. Экспрессия изоформы CYP3A5 в почках участвует в регуляции активности ренин-ангиотензин-альдостероновой системы, альдостерона и реабсорбции натрия. Показано дополнительное значение в регуляции активности альдостерона генетического полиморфизма известного efflux-транспортёра Р-гликопротеина, что также может повышать уровень АД. Антагонисты кальция и амлодипин являются субстратами для CYP3A5. В нескольких зарубежных и отечественном клинических исследованиях показано влияние экспрессии аллеля CYP3A5*1 и вариантного аллеля 3435Т гена АВСВ1 в более выраженном гипотензивном эффекте амлодипина, развитии вазодилатирующих побочных эффектах. При высокой экспрессии CYP3A5*1 выраженность гипотензивного эффекта амлодипина более высокая и сопровождается вазодилатирующими побочными эффектами.

Presented a review of pharmacogenetic markers CYP3A5 and P-glycoprotein and it's role in increasing blood pressure and development of hypertension. Expression of the CYP3A5 isoform in the kidney is involved in the regulation of activity RAAS, aldosterone and sodium reabsorption. An additional value in the regulation of aldosterone activity of the genetic polymorphism of the known efflux- transporter of the P-glycoprotein is shown, which can also increase the level of blood pressure. Calcium antagonists and amlodipine are substrates for CYP3A5. Several foreign and domestic clinical research have shown the effect of the expression of the CYP3A5*1 allele and the variant 3435T allele of the ABCB1 gene in the more powerful hypotensive effect of amlodipine and development of vasodilatation side effects. With high expression of CYP3A5*1 the hypotensive effect of amlodipine is higher and accompanied by vasodilatation side effects.

изоформа CYP3A5Р-гликопротеинальдостеронартериальная гипертонияамлодипинCYP3A5 isoformP-glycoproteinaldosteronearterial hypertensionamlodipineReferencesEhret GB. Genome-wide association studies: contribution of genomics to understanding blood pressure and essential hypertension. Curr Hypertens Rep. 2010;12:17-25. DOI: 10.1007/s11906-009-0086-6.Ehret GB. Genome-wide association studies: contribution of genomics to understanding blood pressure and essential hypertension. Curr Hypertens Rep. 2010;12:17-25. DOI: 10.1007/s11906-009-0086-6.Wang C. Genetic association studies: hypertension and beyond. Hypertension Res. 2011;34(3):294-295. D0I:10.1038/hr.2010.283Wang C. Genetic association studies: hypertension and beyond. Hypertension Res. 2011;34(3):294-295. D0I:10.1038/hr.2010.283Kamide K, Kawano Y, Rakugi H. Pharmacogenomic approaches to study the effects of antihypertensive drugs. Hypertension Research. 2012;35(8):796-799. D0I:10.1038/hr.2012.82Kamide K, Kawano Y, Rakugi H. Pharmacogenomic approaches to study the effects of antihypertensive drugs. Hypertension Research. 2012;35(8):796-799. D0I:10.1038/hr.2012.82Леонова М.В. Фармакогенетика артериальной гипертонии: особенности фармакогенетики торасемида. Фармакогенетика и Фармакогеномика. - 2016. - № 1. - С. 5-8.Леонова М.В. Фармакогенетика артериальной гипертонии: особенности фармакогенетики торасемида. Фармакогенетика и Фармакогеномика. - 2016. - № 1. - С. 5-8.Torrellas C, Carril JC, Cacabelos R. Benefits of pharmacogenetics in the management of hypertension. JPharmacogenomics & Pharmacoproteomics. 2014;5:1-7. D0I:10.4172/2153-0645.1000126Torrellas C, Carril JC, Cacabelos R. Benefits of pharmacogenetics in the management of hypertension. JPharmacogenomics & Pharmacoproteomics. 2014;5:1-7. D0I:10.4172/2153-0645.1000126Siest G, Jeannesson E, Visvikis-Siest S. Enzymes and pharmacogenetics of cardiovascular drugs. Clin Chim Acta. 2007;381(1):26-31. D0I:10.1016/j.cca.2007.02.014Siest G, Jeannesson E, Visvikis-Siest S. Enzymes and pharmacogenetics of cardiovascular drugs. Clin Chim Acta. 2007;381(1):26-31. D0I:10.1016/j.cca.2007.02.014Haehner BD, Gorski JC, Vandenbranden M, et al. Bimodal distribution of renal cytochrome P450 3A activity in humans. Mol Pharmacol. 1996;50(1):52-59.Haehner BD, Gorski JC, Vandenbranden M, et al. Bimodal distribution of renal cytochrome P450 3A activity in humans. Mol Pharmacol. 1996;50(1):52-59.Kuehl P, Zhang J, Lin Y, et al. Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression. Nat Genet. 2001;27(4):383-391. DOI: 10.1038/86882Kuehl P, Zhang J, Lin Y, et al. Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression. Nat Genet. 2001;27(4):383-391. DOI: 10.1038/86882Givens RC, Lin YS, Dowling ALS, et al. CYP3A5 genotype predicts renal CYP3A activity and blood pressure in healthy adults. J Appl Physiol. 2003;95(3):1297-1300. DOI: 10.1152/japplphysiol.00322.2003Givens RC, Lin YS, Dowling ALS, et al. CYP3A5 genotype predicts renal CYP3A activity and blood pressure in healthy adults. J Appl Physiol. 2003;95(3):1297-1300. DOI: 10.1152/japplphysiol.00322.2003Kreutz R, Zuurman M, Kain S, et al. The role of the cytochrome P450 3A5 enzyme for blood pressure regulation in the general Caucasian population. Pharmacogenet Genomics. 2005;15(12):831-837.Kreutz R, Zuurman M, Kain S, et al. The role of the cytochrome P450 3A5 enzyme for blood pressure regulation in the general Caucasian population. Pharmacogenet Genomics. 2005;15(12):831-837.Kivisto KT, Niemi M, Schaeffeler E, et al. CYP3A5 genotype is associated with diagnosis of hypertension in elderly patients. Data from the DEBATE Study. Am J Pharmacogenomics. 2005;5:191-195. DOI: 10.2165/00129785-200505030-00005Kivisto KT, Niemi M, Schaeffeler E, et al. CYP3A5 genotype is associated with diagnosis of hypertension in elderly patients. Data from the DEBATE Study. Am J Pharmacogenomics. 2005;5:191-195. DOI: 10.2165/00129785-200505030-00005Zhang L, Miyaki K, Wang W, Muramatsu M. CYP3A5 polymorphism and sensitivity of blood pressure to dietary salt in Japanese men. J Hum Hypertens. 2010;24(5):345-350. DOI: 10.1038/jhh.2009.74Zhang L, Miyaki K, Wang W, Muramatsu M. CYP3A5 polymorphism and sensitivity of blood pressure to dietary salt in Japanese men. J Hum Hypertens. 2010;24(5):345-350. DOI: 10.1038/jhh.2009.74Thompson EE, Kuttab-Boulos H, Witonsky D, et al. CYP3A variation and the evolution of salt-sensitivity variants. Am J Hum Genet. 2004 Dec; 75(6):1059-1069.Thompson EE, Kuttab-Boulos H, Witonsky D, et al. CYP3A variation and the evolution of salt-sensitivity variants. Am J Hum Genet. 2004 Dec; 75(6):1059-1069.Xi B, Wang C, Liu L, et al. Association of the CYP3A5 polymorphism (6986G>A) with blood pressure and hypertension. Hypertens Res. 2011; 34:1216-1220. DOI: 10.1038/hr.2011.112Xi B, Wang C, Liu L, et al. Association of the CYP3A5 polymorphism (6986G>A) with blood pressure and hypertension. Hypertens Res. 2011; 34:1216-1220. DOI: 10.1038/hr.2011.112Ueda K, Okamura N, Hirai M, et al. Human P-glycoprotein transports cortisol, aldosterone, and dexamethasone, but not progesterone. J Biol Chem 1992;267(34):24248-24252.Ueda K, Okamura N, Hirai M, et al. Human P-glycoprotein transports cortisol, aldosterone, and dexamethasone, but not progesterone. J Biol Chem 1992;267(34):24248-24252.Parler RB, Yates CR, Laizure SC, Weber KT. P-glycoprotein modulates aldosterone plasma disposition and tissue uptake. JCardiovasc Pharmacol. 2006;47(1):55-59.Parler RB, Yates CR, Laizure SC, Weber KT. P-glycoprotein modulates aldosterone plasma disposition and tissue uptake. JCardiovasc Pharmacol. 2006;47(1):55-59.Ernest S, Rajaraman S, Meguesi J, Bello-Reuss EN. Expression of MDR1 (multidrug resistance) gene and its protein in normal human kidney. Nephron. 1977;77(3):284-289. DOI: 10.1159/000190289Ernest S, Rajaraman S, Meguesi J, Bello-Reuss EN. Expression of MDR1 (multidrug resistance) gene and its protein in normal human kidney. Nephron. 1977;77(3):284-289. DOI: 10.1159/000190289Brambila-Tapia AJ. MDR1 (ABCB1) polymorphisms: functional effects and clinical implications. Rev Invest Clin. 2013;65(5):445-454.Brambila-Tapia AJ. MDR1 (ABCB1) polymorphisms: functional effects and clinical implications. Rev Invest Clin. 2013;65(5):445-454.Zolk O, Jacobi J, Pahl A, et al. MDR1 genotype-dependent regulation of the aldosterone system in humans. Pharmacogenet Genomics. 2007;17(2):137-144. DOI: 10.1097/01.fpc.0000239969.46594.d0Zolk O, Jacobi J, Pahl A, et al. MDR1 genotype-dependent regulation of the aldosterone system in humans. Pharmacogenet Genomics. 2007;17(2):137-144. DOI: 10.1097/01.fpc.0000239969.46594.d0Widder JD, Guzik TJ, Mueller CF, et al. Role of the multidrug resistance protein-1 in hypertension and vascular dysfunction caused by angiotensin II. Arterioscler Thromb Vasc Biol. 2007;27(4):762-768. DOI: 10.1161/01.ATV.0000259298.11129.a2Widder JD, Guzik TJ, Mueller CF, et al. Role of the multidrug resistance protein-1 in hypertension and vascular dysfunction caused by angiotensin II. Arterioscler Thromb Vasc Biol. 2007;27(4):762-768. DOI: 10.1161/01.ATV.0000259298.11129.a2Bochud M, Bovet P, Burnier M, Eap CB. CYP3A5 and ABCB1 genes and hypertension. Pharmacogenomics. 2009;10(3):477-487. DOI: 10.2217/14622416.10.3.477Bochud M, Bovet P, Burnier M, Eap CB. CYP3A5 and ABCB1 genes and hypertension. Pharmacogenomics. 2009;10(3):477-487. DOI: 10.2217/14622416.10.3.477Zhang YP, Zuo XC, Huang ZJ, et al. CYP3A5 polymorphism, amlodipine and hypertension. J Hum Hypertens. 2014 Mar;28(3):145-149. DOI: 10.1038/jhh.2013.67Zhang YP, Zuo XC, Huang ZJ, et al. CYP3A5 polymorphism, amlodipine and hypertension. J Hum Hypertens. 2014 Mar;28(3):145-149. DOI: 10.1038/jhh.2013.67Kim KA, Park PW, Lee OJ, et al. Effect of CYP3A5*3 genotype on the pharmacokinetics and pharmacodynamics of amlodipine in healthy Korean subjects. Clin Pharmacol Ther. 2006;80(6):646-656. DOI: 10.1016/j.clpt.2006.09.009Kim KA, Park PW, Lee OJ, et al. Effect of CYP3A5*3 genotype on the pharmacokinetics and pharmacodynamics of amlodipine in healthy Korean subjects. Clin Pharmacol Ther. 2006;80(6):646-656. DOI: 10.1016/j.clpt.2006.09.009Kim KA, Park PW, Park JY. Effect of cytochrome P450 3A5*3 genotype on the stereoselective pharmacokinetics of amlodipine in healthy subjects. Chirality. 2009;21(5):485-491. DOI: 10.1002/chir.20588Kim KA, Park PW, Park JY. Effect of cytochrome P450 3A5*3 genotype on the stereoselective pharmacokinetics of amlodipine in healthy subjects. Chirality. 2009;21(5):485-491. DOI: 10.1002/chir.20588Bhatnagar V, Garcia EP, O’Connor DT, et al. CYP3A4 and CYP3A5 polymorphisms and blood pressure response to amlodipine among African-American men and women with early hypertensive renal disease. Am J Nephrol. 2010;31(2):95-103. DOI: 10.1159/000258688Bhatnagar V, Garcia EP, O’Connor DT, et al. CYP3A4 and CYP3A5 polymorphisms and blood pressure response to amlodipine among African-American men and women with early hypertensive renal disease. Am J Nephrol. 2010;31(2):95-103. DOI: 10.1159/000258688Морозова Т.Е., Ших Н.В., Сычев Д.А., и др. Значение полиморфизма генов АВСВ1 и CYP3A5 в прогнозировании эффективности и безопасности амлодипина у больных артериальной гипертензией 1-2-й степени. ConsilliumMedicum. - 2017. - Т. 19. - № 10. - С. 49-52Морозова Т.Е., Ших Н.В., Сычев Д.А., и др. Значение полиморфизма генов АВСВ1 и CYP3A5 в прогнозировании эффективности и безопасности амлодипина у больных артериальной гипертензией 1-2-й степени. ConsilliumMedicum. - 2017. - Т. 19. - № 10. - С. 49-52

The authors declare that there are no conflicts of interest present.